Bancel Stephane, Chief Executive Officer, subtracted 11,046 shares of Moderna, Inc. (MRNA) from its portfolio at the rate of $20.48 per share valuing $226,222 on Nov 22. The insider left behind 872,650 shares of the company to its portfolio. Currently, the 1st Resistance Point for this stock is $20.68, with a 2nd Resistance Point sitting at $21.37. Meanwhile, this company’s stock has a 1st Support Level at $19.63 and a 2nd Support Level at $19.27. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Moderna, Inc. (MRNA) was $20.00. Moderna, Inc. (MRNA) stock has gained $0.55, or 2.83%, in the past five days. In the last full month, these shares have gained $2.99, or 17.58%. In the past three months, this stock’s price has risen by $6.12, or 44.09%. This year-to-date, Moderna, Inc. (MRNA) shares have gained $4.73, or 30.98%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Moderna, Inc. (MRNA) stock, 50% of short-term indicators suggest that these shares are a “ Buy .” Looking further ahead, 50% of long-term indicators suggest that this stock is a “ Buy .”
With 333,250 K shares outstanding, this company currently has a market capitalization of $6,894,943K. Moderna, Inc. (MRNA) generates $135,070 K in annual sales, amounting to annual net income of -$384,730 K. This stock has generated a 1-Year Total Return of 6.38%, a 3-Year Total Return of 0.00%, and a 5-year Total Return of 0.00%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in 09/19, Moderna, Inc. (MRNA) reported earnings of -$0.37 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.43 per share, representing a 0.06 difference and 13.95% surprise. In the previous quarter ending in 06/19, the reported earnings of -$0.41 represented a 0.01 difference from the consensus estimate calling for -$0.42 per share, which was a 2.38% surprise.
For the current fiscal quarter, which is set to end in 12/2019, the average earnings estimate is -$0.38 per share. This estimate came from a total of 5 Wall Street Analysts. Of those market experts, the high estimate was -$0.19 and the low estimate was -$0.45.
Turning our focus now to insider trading activity, there have been 1 purchases (100,000 shares in total) and 7 sale (138,138 shares in total) in the last 3 months. In the last 6 months, there have been 1 insider buys amounting to 100,000 shares and 7 insider sales amounting to 138,138 shares. In the past full year, 24 insider purchases were made (involving 61,692,583 shares) and 7 insider sell-offs equivalent to 138,138 shares.
Moving onto liquidity, Moderna, Inc. (MRNA) has a Current Ratio of 7.02, a Quick Ratio of 7.02 and a Cash Ratio of 6.83. Looking at this company’s capital structure, its Total Debt to Total Equity is 2.87, its Total Debt to Total Capital is 2.79, and its Total Debt to Total Assets is now 2.24. Looking even further ahead into the future, its Long-Term Debt to Equity is -151.44 and its Long-Term Debt to Total Capital is 2.19.